Nutritional Supplements · Vitamin CRegulatory Approvalcommercialnear-term

FDA Grants Approval for Ascorbic Acid ANDA220172 by STIRA

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/5/2026, 6:30:53 AM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of STIRA's generic Ascorbic Acid introduces a new competitor into the Vitamin C market, which could disrupt pricing and market dynamics. Pharma strategy teams should evaluate the implications for their portfolios and adjust strategies accordingly. Regulatory context from FDA (FDA AP — ASCORBIC ACID (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for Vitamin C products and consider pricing strategies in light of this new entrant. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Nutritional Supplements · Vitamin C, 4 regulatory and 5 competitive items passed relevance filtering for STIRA.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience. This approval allows STIRA to enter the market with a generic version of Ascorbic Acid, potentially impacting pricing and market share of existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ASCORBIC ACID (ORIG) (FDA). Entity match (stira); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval of ANDA220172 indicates compliance with FDA standards, but does not suggest significant regulatory changes for the broader market.

Key Opportunities

The entry of a generic product may lead to price reductions and increased competition, potentially affecting revenue and market share for existing Vitamin C products.
Portfolio teams should assess the competitive landscape for Vitamin C products and consider pricing strategies in light of this new entrant.

What Would Change This Assessment

This becomes more urgent if Monitor market response and sales performance of STIRA's Ascorbic Acid, as well as any potential challenges from competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ASCORBIC ACID (ORIG)
FDAhigh relevance
Entity match (stira); Regulatory pathway relevance (nda)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Rare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
The Innovative Licensing and Access Pathway grants Innovation Passports to investigational products for cancer and dementia
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Homocysteic Acid Biostimulator for Photoaged Facial Skin
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Urinary Vitamin C Loss in Diabetic Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Core-Based Movement and Nutritional Counselling for Stress and Metabolic Outcomes in Overweight Women With Functional Constipation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Nutritional Care After Discharge in Children Term Born-18years Old
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience
Humanexa Signalshigh relevance
Entity match (existing competitors)
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Vasopressin Application ANDA212068 by Sandoz
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi
Humanexa Signalsmedium relevance
Moderate corpus alignment

Gallic acid-driven core-shell nanovehicles enable intestinal adhesion and adipose retention for enhanced oral bioavailability of cholecalciferol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Total organic acids from Cuscuta chinensis Lam. Modulate MDM2 to promote neurogenesis and alleviate depression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intranasal drop of multiplex RNA therapy for SARS-CoV-2 infections: baicalein-enhanced FEN1 nuclease cleaving as a virus buster.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Digeda-8 formula attenuates cholestatic liver injury in rats by restoring bile acid transport and suppressing inflammation: An integrated metabolomics and proteomics approach.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

STIRA
existing competitors

Commercial impact

medium

The entry of a generic product may lead to price reductions and increased competition, potentially affecting revenue and market share for existing Vitamin C products.

Regulatory impact

low

The approval of ANDA220172 indicates compliance with FDA standards, but does not suggest significant regulatory changes for the broader market.

What to watch

Monitor market response and sales performance of STIRA's Ascorbic Acid, as well as any potential challenges from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.